MORPHIOUS: an unsupervised machine learning workflow to detect the activation of microglia and astrocytes.
Authors: Silburt J, Aubert I
In conditions of brain injury and degeneration, defining microglial and astrocytic activation using cellular markers alone remains a challenging task. We developed the MORPHIOUS software package, an unsupervised machine learning workflow which can learn the morphologies of non-activated astrocytes and microglia, and from this information, infer clusters of microglial and astrocytic activation in brain tissue. MORPHIOUS combines a one-class support vector machine with the density-based spatial clustering of applications with noise (DBSCAN) algorithm to identify clusters of microglial and astrocytic activation. Here, activation was triggered by permeabilizing the blood-brain barrier (BBB) in the mouse hippocampus using focused ultrasound (FUS). At 7 day post-treatment, MORPHIOUS was applied to evaluate microglial and astrocytic activation in histological tissue. MORPHIOUS was further evaluated on hippocampal sections of TgCRND8 mice, a model of amyloidosis that is prone to microglial and astrocytic activation. MORPHIOUS defined two classes of microglia, termed focal and proximal, that are spatially adjacent to the activating stimulus. Focal and proximal microglia demonstrated activity-associated features, including increased levels of ionized calcium-binding adapter molecule 1 expression, enlarged soma size, and deramification. MORPHIOUS further identified clusters of astrocytes characterized by activity-related changes in glial fibrillary acidic protein expression and branching. To validate these classifications following FUS, co-localization with activation markers were assessed. Focal and proximal microglia co-localized with the transforming growth factor beta 1, while proximal astrocytes co-localized with Nestin. In TgCRND8 mice, microglial and astrocytic activation clusters were found to correlate with amyloid-β plaque load. Thus, by only referencing control microglial and astrocytic morphologies, MORPHIOUS identified regions of interest corresponding to microglial and astrocytic activation. Overall, our algorithm is a reliable and sensitive method for characterizing microglial and astrocytic activation following FUS-induced BBB permeability and in animal models of neurodegeneration.
Introduction
Purpose
BBB opening without drug delivery
Study Objective
To develop and validate MORPHIOUS, an unsupervised machine-learning workflow that learns baseline microglial and astrocytic morphologies and identifies spatial clusters of glial activation in brain tissue.
Animal model / Human subject
Mouse (Mus musculus): C57BL/6J males, 3.5 months old (N=4); TgCRND8 transgenic mice, 7 months old (2 males, 2 females); non‑transgenic C3H/C57BL6 controls, 7 months old (2 males, 2 females)
Disease model
Focused ultrasound-induced blood–brain barrier (BBB) permeability; TgCRND8 amyloidosis model (Alzheimer's disease model)
MRI or image guidance method
MRI-guided: 7.0-T MRI with T2-weighted axial scans used to position four focal spots targeting the hippocampus; T1-weighted Gadovist enhancement used to confirm BBB permeability.
Targeted brain region(s)
Hippocampus
Cargo name and characteristics
Gadovist (gadobutrol) — a small-molecule, gadolinium-based MRI contrast agent administered intravenously (0.2 ml/kg) to confirm BBB permeability
Route of administration
Intravenous (tail vein injection)
Outcomes and Safety
Summary of Outcomes
Unilateral focused ultrasound (with microbubbles) to the hippocampus produced spatially clustered microglial activation (two classes: focal and proximal; showing increased IBA1, enlarged soma, deramification and co‑localization with TGFβ1/CD68) and proximal astrocytic activation (increased GFAP intensity/branching and Nestin co‑expression) that overlapped spatially and correlated with amyloid‑β in TgCRND8 mice; no multiple FUS parameter variants were tested.
Duration of biological effect
7 days
Safety-related matter
The paper does not report specific safety concerns or adverse effects; it describes glial activation following focused ultrasound–induced BBB permeability but does not document deleterious outcomes or adverse events.
Brain Region
Ultrasound Parameters
Ultrasound instrument
In-house focused ultrasound system with a spherically focused transducer (1.68 MHz; 75 mm diameter; 60 mm radius of curvature); manufacturer: None
FUS Frequency
1.68 MHz
FUS Mode
pulsed
Pulse duration
10 ms
Duration of a single FUS session
120 s
Focal Characteristics
focal depth: None; focal length: 60 mm (radius of curvature of the spherically focused transducer); aperture size: 75 mm (transducer diameter)
Treatment frequency
single
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search